June 26th 2024
Ensemble No.2, or ENS-002, is an investigational live biotherapeutic product first detected by Concerto Biosciences using its kChip technology.
June 25th 2024
Authorization for Eli Lilly's Ebglyss is based on positive results from the ADvocate 1, ADvocate 2, and ADhere studies.
June 21st 2024
Botanix Pharmaceuticals announced the approval of its sofpironium topical gel, 12.45% for adults and children ages 9 and older.
June 20th 2024
Stefan Weiss, MD, MBA, explains next steps for the oral treatment after the completion of phase 1b enrollment.
June 13th 2024
LEO Pharma's Adbry, a single-dose autoinjector, is expected to become available to patients in the coming months.
Patient enrollment complete for tapinarof long-term safety study for psoriasis
Dermavant announces the enrollment completion for their long-term safety study investigating tapinarof in adults with plaque psoriasis as a part of the PSOARING 1 and PSOARING 2 phase 3 program.